Public interest and what is in the best public interest can vary from court to court, and in the case of Amgen v Sanofi, it has yet to be determined if public interest will be considered, explained Ha Kung Wong, JD, partner at Fitzpatrick, Cella, Harper and Scinto.
Amgen v Sanof
Public interest and what is in the best public interest can vary from court to court, and in the case of i, it has yet to be determined if public interest will be considered, explained Ha Kung Wong, JD, partner at Fitzpatrick, Cella, Harper and Scinto.
Transcript
Will the public interest in having competition within drug classes, such as in the ongoing litigation concerning PCSK9 patents, have an impact on the courts’ rulings?
Well, public interest is an interesting question because of lot of that can be subjective from court to court. But historically, competition per se hasn’t had much of an impact on courts’ rulings relating to small molecule drugs and medical devices. So in those situations, where the courts haven’t seen much evidence of physician preference for or greater efficacy of an infringing product, they will generally determine that the public interest actually lies in having a strong patent system and not in having just competing products in a market for the sake of competition.
But, where the courts have seen evidence of physician preference or product superiority they do tend to find that the public interest lies in keeping a superior product on the market. In Amgen v Sanofi, for example, Sanofi is now trying to demonstrate that the clinical trials suggest that its PCSK9 inhibitor is superior. Regardless, it’s yet to be seen if the public interest factor would be dispositive in this situation, and if not, to what extent it will be considered.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More